Key result
Higher ACE2 activity in patients with transthyretin amyloid cardiomyopathy is associated with higher NT-proBNP, biventricular dysfunction, and adverse cardiac outcomes.
Why the study?
The circulating renin-angiotensin-aldosterone system patterns in transthyretin amyloid cardiomyopathy and their relationship with clinical parameters and prognosis were not well characterized.
In patients with ATTR-CM, increased ACE2 activity and a shift toward the alternative RAAS axis are associated with more advanced disease and predict adverse cardiac outcomes.
AIM: This study aimed to characterize circulating renin-angiotensin-aldosterone system (RAAS) patterns in transthyretin amyloid cardiomyopathy (ATTR-CM), examine their relationship with clinical and echocardiographic parameters and determine their prognostic value. METHODS: In this prospective study, ATTR-CM patients underwent serum quantification of classical (angiotensin I-IV, aldosterone) and alternative (angiotensin 1-7, angiotensin 1-5) RAAS peptides and angiotensin converting enzyme 2 (ACE2) activity using mass spectrometry. RAAS inhibitor use was recorded. Associations of RAAS peptides with N-terminal pro brain natriuretic peptide (NT-proBNP) and echocardiographic parameters were analyzed. Prognostic associations with the composite endpoint of HF hospitalization or cardiac death were assessed using Kaplan-Meier curves stratified by median peptide values. RESULTS: Among 137 patients, RAAS inhibitor use included ACEi (21.2%), ARBs (34.3%), ARNIs (7.3%) and none (26.0%). RAAS profiles were consistent with the expected effects of the respective RAAS inhibitors. During a median follow-up of 1.6 years, 49 patients (36%) experienced the composite endpoint. Patients with adverse cardiac events had higher ACE2 activity (p<0.001) and alternative RAAS peptides (angiotensin 1-7: p=0.007; angiotensin 1-5: p<0.001). Higher ACE2 activity was associated with higher NT-proBNP (p<0.001) and more advanced echocardiographic markers of biventricular dysfunction. In Kaplan Meier analysis, ACE2 above median predicted adverse cardiac outcomes (p=0.017), while classical RAAS peptides were not predictive. CONCLUSION: ATTR-CM patients exhibit distinct RAAS profiles, with increased ACE2 activity and a shift toward the alternative RAAS axis in more advanced disease. Higher ACE2 activity is associated with higher NT-proBNP, biventricular dysfunction and adverse cardiac outcomes, suggesting that ACE2 may represent a promising marker for risk stratification in ATTR-CM.
No takes yet. Share an insight, caveat, or question.
Kronberger et al. (2026) studied this question. Higher ACE2 activity in patients with transthyretin amyloid cardiomyopathy is associated with higher NT-proBNP, biventricular dysfunction, and adverse cardiac outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: